Aim To temporally and externally validate our previously developed prediction model, which used data from University Hospitals Birmingham to identify inpatients with diabetes at high risk of adverse outcome (mortality or excessive length of stay), in order to demonstrate its applicability to other hospital populations within the UK.
Introduction
Diabetes mellitus is the most common documented comorbidity in a hospital setting, affecting 17% of all adult admissions [1] . Hospitalized patients with diabetes have high infection rates [2] [3] [4] [5] , longer length of stay (1-3 more days compared with patients without diabetes) [6] [7] [8] and a higher mortality rate (6.4% higher) [9] . The reasons for poor clinical outcomes are less well understood but poor glycaemic control and foot disease have been implicated as potential reasons [10] [11] [12] [13] . In 2009/2010, people with diabetes accounted for 11% of National Health Service (NHS) expenditure on in-hospital care, totalling approximately £2.5 bn [14] .
Inpatients with diabetes do not receive optimal care: only 30% have their feet examined in the first 24 h and only 60% of those admitted with active foot disease are referred to multidisciplinary foot care teams within the first 24 h of admission [1] , despite these standards being recommended by the National Institute for Health and Care Excellence (NICE) [15] . Furthermore, antidiabetes medication errors (occurring in 21% of patient admissions) [1] may result in patient harm, including death [16] . Patient surveys and qualitative studies have also highlighted issues around incorrect medications, disempowerment, poor meal timing and choice, and inadequate specialist team input into diabetes care [1, 17] .
Diabetes specialist teams for inpatient diabetes care may improve patient outcomes and reduce length of stay [18] [19] [20] [21] ; however, with rising numbers of inpatients with diabetes there is a need to upskill ward staff to manage the generic needs of people with diabetes and only refer to a specialist team for 'complex needs'. The 'ThinkGlucose' campaign [22] recommended criteria for inpatient referral to diabetes specialist teams but, despite widespread campaigning, only 69% of patients meeting these criteria were seen by the diabetes specialist team [1] . Very little is known regarding whether referrals were timely and if the reason for referral could have been avoided by implementing optimal care at an earlier stage.
There is a need to develop tools to identify patients in need of diabetes specialist team review early during their admission, preferably before they experience an adverse outcome. Such tools could be incorporated into the electronic medical records (EMR).
Using data from University Hospitals Birmingham NHS Foundation Trust (UHB), our research team has previously developed and internally validated a prediction model that identifies hospitalized patients with diabetes who are at risk of adverse outcome while in hospital (mortality or excessive length of stay) [23] . Unique features of the prediction model are: it does not require the reason for admission or information on comorbidities, as routinely available data including blood results are used to predict risk, and it has the ability to identify patients at risk of adverse outcome within the first 24 h of admission.
The aim of the present study was to temporally and externally validate this prediction model, in order to determine whether it performs equally well in more recent data and in other hospital settings before trialling for clinical practice.
Methods

Setting and data sources
The prediction model was developed using data from UHB from 2007 to 2010 [23] . Temporal validation was carried out using inpatient data from 1 January to 31 December 2014 from UHB. External validation was carried out using inpatient data from 1 January to 31 December 2014 from the Heart of England NHS Foundation Trust (HEFT) and inpatient data from 1 January to 30 June 2014 from Ipswich Hospital.
UHB is a tertiary hospital in the West Midlands with over 1200 beds, providing secondary care to an ethnically diverse population. HEFT is a large hospital trust, comprising several hospitals across the West Midlands (Heartlands, Good Hope and Solihull), with a total of more than 1550 beds; the trust serves an ethnically and socio-economically diverse range of communities. Ipswich Hospital is located in the East of England; it is a district hospital with~800 beds, and provides secondary care to a slightly older, less deprived and less ethnically diverse population.
Participants
All inpatients with diabetes aged ≥16 years were included in the analysis. For HEFT, data were only available for patients aged ≥18 years.
Outcome definition
Adverse outcome was a composite of excessive length of hospital stay or death [23] . Excessive length of hospital stay was defined as an excess length of stay >75 th centile for all admissions for people with diabetes. Excess length of stay was defined as the difference between the actual length of stay for the diabetic inpatient admission and the median length of stay calculated in all inpatients with diabetes admitted in the same primary diagnosis category. In sensitivity analysis, the median length of stay was calculated in inpatients without diabetes (UHB only; these data were not available for HEFT and Ipswich). The primary diagnosis category was defined using the 260 group categories in the Healthcare Research and Quality clinical classification software [24] .
Definitions of variables
Diabetes was defined using discharge diagnostic codes and prescription data. The diagnostic codes used to indicate diabetes were International Classification of Diseases version 10 codes E10-E14 or any of their sub-classifications.
What's new?
• National audits have highlighted suboptimal care for inpatients with diabetes. Evidence suggests targeted review of hospitalized patients with diabetes by a specialist team, using electronic triggers, could improve clinical outcomes. To date, no externally validated tool to identify inpatients with diabetes at risk of adverse outcomes has been published.
• In the present study we temporally and externally validated a prediction model to identify inpatients with diabetes who are at high risk of developing adverse outcomes.
• Model performance was found to be optimal and sufficient for further evaluation in clinical practice, where it may be used to prevent harm, improve clinical outcomes, and prioritize care for inpatients with diabetes.
ª 2018 Diabetes UK Additionally, patients were categorized as having diabetes if they were on any of type of insulin, sulfonylureas, biguanides or other antidiabetes drugs, excluding patients on metformin alone with a discharge diagnostic code for polycystic ovarian syndrome or patients who received short-or rapid-acting insulin alone [25] . All inpatients with diabetes were included, irrespective of primary diagnosis. The variables included in the model were: age; sex; ethnicity; admission type (elective or emergency); intensive therapy unit admission (binary); insulin therapy (binary); and presence/absence of foot disease (binary). The following clinical pathology test results were also included: albumin; sodium; potassium; haemoglobin; C-reactive protein; estimated GFR; and neutrophil count. Insulin therapy was defined as one or more prescription for insulin during the admission; these data were not available for Ipswich, therefore, insulin prescription prior to admission was used. Presence of foot disease was identified using both discharge diagnostic codes and OPCS Classification of Interventions and Procedures codes recorded at any time during the admission [13] . In instances where a patient had multiple blood tests during a single admission, the earliest test result for the admission was used.
Normal blood test results were defined as follows: albumin ≥ 35 g/l; sodium 135-144 mmol/l; potassium 3-5.9 mmol/l; haemoglobin ≥ 12 g/dl; C-reactive protein 0-9 mg/l; estimated GFR ≥ 90 ml/min/1.73 m 2 ; and neutrophil count <7.9 9 10 9 /l.
Definition of model
Coefficients of the logistic regression model are presented in Supporting Information Table S1 .
Analysis
For patients with multiple admissions, a single, randomly selected admission was included in the analysis; a sensitivity analysis was carried out including all admissions. Data were complete for all variables except clinical pathology (blood) test results. Missing clinical pathology test results were replaced using multiple imputation (10 imputations); this was performed using chained equations and predictive mean matching. In additional sensitivity analysis, missing test results were replaced with values in the normal range to better reflect use of the model in a hospital setting.
Performance assessment
Model discrimination was assessed by plotting a receiveroperating characteristic curve and calculating area under the curve (AUC, or Harrell's C-statistic). Sensitivity, specificity and positive and negative predictive values were calculated at a ≥25% predicted chance of adverse outcome; this was found to be the optimal threshold, at which the sum of sensitivity and specificity was maximal (Youden's index), during development of the model. Test statistics generated from the 10 imputed datasets were combined using Rubin's rule. Model calibration was assessed by plotting predicted probabilities of outcome against observed probabilities of outcome, by decile, with overlaid locally weighted scatterplot smoothing (LOWESS) curve.
Results
Temporal validation
A total of 6533 inpatients with diabetes contributing to a total of 11 019 hospital admissions at UHB were included in the temporal validation analysis. Of these, 27.5% (n = 1797) had an adverse outcome: 1529 patients had an excessive length of stay, 164 died, and 104 had an excessive length of stay ending in death. Baseline patient characteristics are presented in Table 1 (see also (Table S3) . In temporal validation, replacing missing values using multiple imputation, model discrimination was good: the AUC was 0.797 (95% CI 0.785-0.810). At a threshold of ≥ 25% predicted probability of adverse event, the sensitivity was 69.5% (95% CI 67.3-71.6) and the positive predictive value was 51.3% (95% CI 49.2-53.3; Table 2 ).
In the three sensitivity analyses, replacing missing values with values in the normal range, calculating the median length of stay in inpatients without diabetes, and using all admissions for inpatients with diabetes (rather than just a single randomly selected admission for each patient) made very little difference to model performance (Figs 1a and 2  and Tables 2, S4 and S5) .
Model calibration was good, with the LOWESS curve in close proximity to the 45 degree line, i.e. predicted probabilities were similar to observed probabilities (Fig. 1d) .
External validation
A total of 10 690 inpatients with diabetes contributing to a total of 16 568 hospital admissions at HEFT, and 1885 patients contributing to a total of 2554 hospital admissions at Ipswich were included in the external validation analyses. In the HEFT dataset, 27.8% of patients (n = 2973) had an adverse outcome: 2423 patients had an excessive length of stay, 301 died, and 249 had an excessive length of stay ending in death. In the Ipswich dataset, 27.4% of patients (n = 517) had an adverse outcome: 425 patients had an excessive length of stay, 46 died, and 46 had an excessive length of stay ending in death. Baseline patient characteristics are presented in Table 1 (see also Table S2 ). In both the HEFT and Ipswich datasets, there were more emergency admissions and fewer intensive care unit admissions compared with UHB. Fewer patients at HEFT had foot disease. Insulin treatment rates were lower at Ipswich, with little difference between rates in patients with or without adverse outcome.
In the HEFT external validation dataset, replacing missing values using multiple imputation, the AUC was 0.758 (95% CI 0.747-0.768). At a threshold of ≥25% predicted probability of adverse event, the sensitivity was 72.6% (95% CI 70.9-74.2) and the positive predictive value was 45.1% (95% CI 43.7-46.5; Table 2 ).
In the Ipswich external validation dataset, replacing missing values using multiple imputation, the AUC was 0.736 (95% CI 0.711-0.761). At a threshold of ≥25% predicted probability of adverse event, the sensitivity was 63.4% (95% CI 59.1-67.6) and positive predictive value was 43.8% (95% CI 40.3-47.5; Table 2 ).
In two sensitivity analyses, missing values were replaced with values in the normal range, and model performance was assessed in all admissions for inpatients with diabetes (rather than using a single randomly selected admission for each patient); this made little difference to the model performance (Table 2, Figs 1b,c and 2, and Table S5 ). Model calibration was good in both datasets (Figs 1e,f) .
Discussion
Our previously published model performed well, with an AUC of 0.80, 0.76 and 0.74 in the UHB, HEFT and Ipswich datasets, respectively. It was able to identify (sensitivity) two-thirds to three-quarters of patients at high risk of adverse outcomes (63% at Ipswich Hospital, 70% at UHB and 73% at HEFT). Among those who were predicted by the model to have an adverse outcome, 44% in Ipswich Hospital, 45% in HEFT and 51% at UHB (positive predictive value) went on to have an adverse event defined as death or excessive length of stay. The results were robust in our sensitivity analyses; performance improved when missing values were replaced with normal values, which better reflects implementation in a clinical setting. Prediction models can become outdated with change in population demography, better linkage of data systems, better therapeutic options and care pathways, and improvement in data recording; however, model performance at UHB was similar after nearly 5 years, with an AUC of 0.802 (95% CI 0.795-0.808) and 0.804 (95% CI 0.792-0.816) [23] in the development and temporal validation datasets, respectively (median length of stay calculated in inpatients without diabetes). Specificity increased from 70% in the derivation dataset to 75% in the temporal validation dataset, and positive predictive value remained similar, changing from 49% to 51%. Sensitivity was lower at 70% in temporal validation compared with 76% in the derivation dataset. This can be attributed in part to improved linkage of EMR data to Patient Administrative System data in recent years (> 95% compared with 77% previously [25] ). This means patients who were less ill may not have been included in the model development dataset as they would have been discharged before being entered into the EMR, leading to some dissimilarity between the patient cohorts.
Model performance at Ipswich Hospital was slightly inferior. This may be explained by the fact that only data from the first 6 months of the calendar year were available, that the population was less ethnically diverse compared with the other two hospitals and that the definition of insulin use differed. The observed differences in insulin use may be attributable to a difference in the prescription information used (insulin prior to admission rather than during) and to the method of data recording (use of in-house insulin recording rather than electronic prescription data, as at UHB and HEFT); however, the performance measures were still comparable with many clinically utilised prediction models, such as the Rockall score for outcomes of upper gastrointestinal bleed [26] .
Overall, the results of the present analysis show that the model is both temporally and externally valid: it performed well in both more recent data from the original hospital (UHB) and in other hospitals with sociodemographically The strengths of the present study include the external validation across two distinctly different hospital settings, datasets with large numbers of patients and events, robust methodology including a number of sensitivity analyses, and being the first study to derive and validate a prediction model to identify adverse events in hospitalized patients with diabetes based on routinely collected data close to the time of admission. Only two other algorithms that aim to identify patients at risk of hypoglycaemia exist for inpatients with diabetes, but these were not externally validated [27, 28] .
Validation of the model is, however, limited to hospitals in the UK, and data from Ipswich Hospital had limitations that prevented us from optimally demonstrating the performance in a district general hospital setting.
One of the unique features of the model is that it uses routinely collected data on admission and can therefore be incorporated into the EMR without any additional information needs; however, the model could only be incorporated where there are robust EMR; currently only a third of UK hospitals are fully utilising EMR, while a further 31% are making partial use of EMR [1] . Nevertheless the UK government has encouraged hospitals to procure EMR and replace paper-based medical records within the next few ª 2018 Diabetes UK years [29] . It is, therefore, the right time to develop and evaluate novel tools that could result in better clinical outcomes and healthcare efficiency.
The model has potential clinical utility and could help shape care pathways for hospitalized patients with diabetes. We propose to develop electronic care pathways and test direct and indirect triggers that could alert diabetes specialist teams or other health professionals to take timely actions. Direct triggers will include alerts for recurrent or severe hypoglycaemia, insulin infusions over 48 h and persistent hyperglycaemia. The prediction model will serve as an indirect trigger and will aim to identify patients at high risk of adverse events (Fig. 3) . If the model were implemented, about half of people with diabetes flagged up by a system like this would experience an adverse outcome. Furthermore, most of those who will experience an adverse outcome would be flagged up. This suggests the model might be useful in identifying those individuals who might benefit from additional input. Clinical judgement might play a further role in identifying those flagged up who were most likely to benefit from input. However, it should be noted that, at present, there is a lack of strong evidence regarding whether or not specialist inpatient diabetes teams can reduce mortality; this is an area that requires further research.
One criticism of the model is that it may identify ill patients who might not particularly benefit from review by the diabetes specialist team. Another criticism is that most covariates and the outcomes in the model are not diabetesspecific, and the model may therefore perform well in other chronic conditions to predict length of stay and mortality. However, we have shown that variables in the model can predict hypoglycaemia [28] and it is therefore reasonable to hypothesize that a care pathway with risk stratification can enable harm reduction and better clinical endpoints for inpatients with diabetes. For example, an algorithm for hypoglycaemia developed and implemented in a hospital in the USA resulted in a 68% reduction in severe hypoglycaemic episodes [27] .
In conclusion, the prediction model to identify patients with diabetes at high risk of developing an adverse outcome while in hospital performed well when externally validated. The model now needs to be tested for clinical utility in hospitalized patients with diabetes in England. If found to be of clinical benefit, it should be further externally validated in other countries with EMR before implementation in their hospital setting. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
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